Further studies showed that low-dose oral prednisolone maintenance therapy decreased the CSF CXCL10 levels and is associated with good functional prognosis, suggesting CSF CXCL10 is a promising surrogate marker for HAM/TSP treatment (Tamaki et al., 2019). The gene discussed is CXCL10; the disease is tropical spastic paraparesis.